EpiDisease

What EpiDisease does

EpiDisease, S.L. is a privately held Spanish biotechnology company incorporated in June 2014 as the first spin-off of CIBER (Centro de Investigación Biomédica en Red), headquartered at the Parc Científic Universitat de València in Paterna (Valencia). The company develops in vitro diagnostic (IVD) tools that integrate genetics, epigenetics, and artificial intelligence to address complex pathologies, with a primary focus on Adolescent Idiopathic Scoliosis (AIS) and sepsis/septic shock, alongside secondary work in Type 2 Diabetes Mellitus prevention, skin lesion characterization, and biological age estimation.

Its core product portfolio comprises ScoliGEN (a 20-SNP qPCR-based genetic susceptibility test for AIS), ScoliMIR (a microRNA-panel epigenetic test producing a Scoliosis Risk Index with 96% sensitivity and 86% specificity), ScoliVIEW (an AI-driven computer vision tool for automated Cobb angle measurement), HistSHOCK (a mass spectrometry-based IVD kit quantifying circulating histones H3 and H2B in plasma for sepsis diagnosis, severity stratification, and DIC risk prediction), SepAST (an EU-registered ML medical software for sepsis progression and treatment response forecasting), and AgingMETRIX (a single-gene methylation epigenetic clock). HistSHOCK technology is patented and granted across Europe, Japan, the United States, China, and Hong Kong.

EpiDisease generates revenue through two primary streams: (1) per-test diagnostic services sold directly to patients and physicians via its e-commerce-enabled website, with sample processing at its authorized diagnostic center (registration 22325 by the Valencian Government Health Department), using a one-time license/pay-as-you-go pricing model processed via Bankia TPV Virtual; and (2) R&D services and collaborations with pharmaceutical companies, hospitals, and research institutions, including biomarker identification, omics/AI validation, bioinformatics analysis, and Illumina array services under project-based contracts and grants. The company has secured over €2.4 million in cumulative non-dilutive funding from CDTI, EUROSTARS, Fundación Botín, and Generalitat Valenciana, and has a strategic companion diagnostic co-development with Matisse Pharmaceuticals BV (eHISTOCURE project) targeting the M6229 sepsis therapeutic.

Name

EpiDisease

Legal name

EPIDISEASE, S.L.

Website

https://epidisease.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

EpiDisease is a Spanish biotechnology company developing epigenetic and genetic in vitro diagnostic (IVD) tools that combine genetics, epigenetics, and AI to serve clinicians and patients in scoliosis, sepsis, and related complex pathology management.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro industry

PRIMARYHLAGANAF

Epigenomics & Chromatin Profiling Services

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

SECONDARYHLAGANAI

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)

SECONDARYHLAAALAO

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)

Healthcare & Life Sciences/Biotechnology & Biologics/Diagnostics (Biotech-related)

SECONDARYHLAGAEAD

Genomics & Molecular Diagnostics (Trial Support)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

SECONDARYHLAGAJAD

Bioinformatics & Multi-omics Analysis Software

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

• Epigenetic diagnostics
• In vitro diagnostics
• Genetic testing services
• Biomarker discovery
• Medical imaging AI

Headquarters

HQ city

Paterna

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Testing Services: EpiDisease operates an authorized diagnostic center (authorized by the Valencian Government Health Department, registration number 22325) providing genetic and epigenetic testing services. Tests such as ScoliGEN are offered as LDTs (Laboratory Developed Tests) purchased directly by patients or ordered by physicians via the company's website. Results are delivered electronically within specified timeframes. Revenue is generated on a per-test basis through direct purchases.
2. R&D Services and Collaborations: EpiDisease provides research and development services including biomarker identification and validation using omics and AI, bioinformatics analysis, and Illumina array services to pharmaceutical companies, hospitals, and research institutions. Revenue derives from project-based contracts and grants. The company has received significant public funding (e.g., €1.9M CDTI grant for HistSHOCK, €524K EUROSTARS for eHISTOCURE) which supports R&D activities.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

EpiDisease develops and sells in vitro diagnostic (IVD) tools and services that combine genetics, epigenetics, and artificial intelligence to manage complex pathologies. Its portfolio includes genetic susceptibility tests (ScoliGEN), epigenetic microRNA diagnostic tests (ScoliMIR), AI-based medical imaging software for scoliosis (ScoliVIEW), plasma-based histone biomarker IVD kits for sepsis (HistSHOCK), and predictive machine learning software for ICU treatment response (SepAST). The company also provides R&D services including biomarker identification, validation using omics and AI, and Illumina EPIC array analysis for pharmaceutical companies, hospitals, and research institutions.

Differentiator

Problem solved

Functional benefit

Brands

• ScoliGEN: Genetic test evaluating susceptibility to develop Adolescent Idiopathic Scoliosis (AIS), analyzing 20 SNPs in genes associated with disease risk and progression.
• ScoliMIR
• ScoliVIEW
• HistSHOCK
• SepAST
• AgingMETRIX
• ScoliPro

Products and services

• ScoliGEN Genetic test evaluating susceptibility to Adolescent Idiopathic Scoliosis (AIS) based on the analysis of 20 single nucleotide polymorphisms (SNPs) located in genes associated with disease onset and progression risk. Genotyping is performed via qPCR using TaqMan Genotyping Assays, with results combined into a polygenic risk score (90% sensitivity, 82% NPV). Offered as an LDT through the authorized diagnostic center and via the e-commerce website with saliva sample collection.
• ScoliMIR Epigenetic IVD test based on measuring a dynamic microRNA panel in peripheral blood samples. Data is processed through proprietary algorithms to calculate a Scoliosis Risk Index (SRI) providing AIS diagnosis, with Sensitivity 96%, Specificity 86%, Positive Predictive Value 95%, and Negative Predictive Value 92%.
• ScoliVIEW Web-based AI tool for automated Cobb angle measurement on DICOM, JPEG, and PNG images, eliminating documented intra- and inter-observer variation of 4°-8° from manual measurements. Incorporates machine learning algorithms for enhanced robustness and processes medical images in seconds.
• HistSHOCK IVD Kit IVD kit for measuring circulating histone levels (H3 and H2B) using mass spectrometry in plasma samples. Validated biomarkers for diagnosing, stratifying by severity, and monitoring sepsis, septic shock, and disseminated intravascular coagulation (DIC) progression. Technology patented in Europe (EP3535587), Japan, United States, China, and Hong Kong.
• SepAST Medical Software Web-based medical software tool (European registration number 018645153) using machine learning algorithms and biomarkers combined with clinical data to predict clinical progression of sepsis patients and anticipate treatment responses, supporting predictive and precision medicine in ICUs.
• AgingMETRIX Simplified epigenetic clock based on the methylation pattern of a single gene, capable of estimating biological age. Designed to be accessible and applicable across various clinical and research settings.
• R&D Services and Biomarker Analysis R&D services including biomarker identification and validation using omics and AI, bioinformatics analysis, and Illumina EPIC array services provided to pharmaceutical companies, hospitals, and research institutions. Revenue derives from project-based contracts and grants (e.g., CPP2021-008643 project for sepsis biomarker identification).

Quantifiable outcome

• ScoliGEN achieves 90% sensitivity, 39% specificity, 56% positive predictive value, and 82% negative predictive value for AIS risk assessment.
• +5 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature8 records

Partnerships

One partnership is on record.

• Matisse Pharmaceuticals BVcoreStrategic or Co-development PartnerEpiDisease and Matisse Pharmaceuticals BV are jointly developing HistSHOCK CDx as a companion diagnostic for the M6229 sepsis therapy under the eHISTOCURE project. Matisse is a clinical-stage biopharmaceutical company developing therapeutic molecules for sepsis and septic shock treatment. The CDx test uses LC-MS/MS to quantify circulating histones and identify patients most likely to respond to M6229. The project received €524,000 through the EUROSTARS program with partial CDTI support.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• T2 Biosystems: US-listed molecular diagnostics company focused on rapid sepsis and bloodstream infection detection. Directly comparable to EpiDisease on the sepsis-diagnostic thesis and the strategy of displacing blood culture with faster, biomarker-based IVDs in the ICU.
• VolitionRx: Nucleosomics-based epigenetics diagnostics company developing blood-based tests for cancer and other diseases. Closely mirrors EpiDisease's model of translating epigenetic biomarker science into commercial IVD products.
• MDxHealth: Commercial-stage epigenetics/molecular diagnostics company with a urology-focused menu of methylation-based IVD tests. Comparable as a small-cap pure-play epigenetic diagnostics commercializer pursuing CE-IVD-marked IVDs.
• Genetic Technologies: Australian-listed predictive risk assessment company offering genetic and epigenetic-based tests directly to consumers and clinicians. Closely mirrors EpiDisease's ScoliGEN/ScoliMIR D2C-plus-physician-channel motion in polygenic risk and epigenetic disease risk testing.

Emerging players

• Nucleix: Israel-based epigenetic diagnostics company focused on blood-based cancer screening assays using methylation biomarkers. Directly comparable business model of using proprietary epigenetic biomarkers for non-invasive IVD products.
• Cambridge Epigenetix: UK-based epigenomics company developing methylation detection technologies for research and clinical use. Comparable as an early-stage platform play in epigenetic biomarker technology with both tools and diagnostic applications.
• Inflammatix: Host-response diagnostics company developing rapid point-of-care and blood-based tests for acute infections and sepsis. Comparable on the sepsis-diagnostic thesis, target customer (ICU/ED physicians), and biomarker-plus-AI approach to stratification.

Broad incumbents

• QIAGEN: Major molecular diagnostics and sample-technology provider with a companion diagnostics franchise. Relevant both as a competitor in epigenetic/molecular diagnostics and as a potential strategic acquirer of niche IVD platforms like EpiDisease.
• bioMérieux: Global in vitro diagnostics incumbent with a leading sepsis and hospital microbiology franchise (e.g., BACT/ALERT, VIDAS). Competes with EpiDisease for the same ICU budgets and represents the dominant distribution and installed-base competitor.
• Roche Diagnostics: Largest global IVD company with broad sepsis biomarker menus (e.g., procalcitonin Elecsys) and dominant hospital channel reach. The benchmark broad incumbent whose distribution and regulatory capabilities EpiDisease must contend with.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/epidisease-sl
• Xx.com/epidisease

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EpiDisease